In Vitro Models of Liver and Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02436564|
Recruitment Status : Unknown
Verified July 2016 by Dr. Kourosh Saeb-Parsy, Cambridge University Hospitals NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : May 7, 2015
Last Update Posted : July 14, 2016
The primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue. The secondary objective is to study the genetic and cellular biology of cancer of the liver, biliary tract and the pancreas. As well the investigators hope to compare molecular and cellular biology of cancer cells with normal cells as well as potentially test the efficacy of current and future anti-cancer therapies.
Samples will be collected from tissue that has been resected as part of the treatment for a patient diagnosed with liver, bile duct or pancreas cancer.
|Condition or disease||Intervention/treatment|
|Cholangiocarcinoma Hepatocellular Carcinoma Pancreatic Neoplasm||Genetic: Organoid in vitro culture|
|Study Type :||Observational|
|Estimated Enrollment :||75 participants|
|Official Title:||A Study Designed to Develop in Vitro Models of Liver, Biliary and Pancreatic Cancer for the Investigation of Tumour Biology and Potential Therapies|
|Study Start Date :||July 2015|
|Estimated Primary Completion Date :||September 2018|
- Genetic: Organoid in vitro culture
Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
- Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months. [ Time Frame: 3 years ]
- Proportion of tumour-derived organoids that are genetically identical to the source tumour. [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02436564
|Contact: Kourosh Saeb-Parsy, PhD, FRCS||(+44 1223 7) firstname.lastname@example.org|
|Contact: Nikitas Georgakopoulos, BScemail@example.com|
|Cambridge, United Kingdom, CB2 0QQ|
|Contact: Andrew Bradley, PhD, FRCS (3)36976 (7)62001 firstname.lastname@example.org|
|Principal Investigator:||Kourosh Saeb-Parsy, PhD, FRCS||Cambridge Univeristy Hospitals|